Features of SOX11− MCL
| Patient . | Age, y/sex . | CD markers by flow cytometry . | Diagnostic tissue . | Growth pattern lymphoid tissue . | Blastoid variant . | MIB1, % . | Growth pattern BM . | p53* . | Indolent† . | MIPI . | Stage . | Splenomegaly . | > 4 nodal sites . | Extra nodal . | Leukemic . | B symptoms . | ECOG score > 2 . | TTT, d . | ASCT . | Follow-up, d (status) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 89.9/M | +/5/L, −23/10 | LN | Diffuse | 0 | 13 | Nodular | 0 | 0 | 3 | 4 | 0 | 1 | 0 | 0 | 0 | 0 | 24 | 0 | 1775 (D) |
| 15 | 87.1/F | +20/5/23dim/L, −10 | Stomach | NA | 0 | 12 | Nodular | 0 | 1 | 3 | 4 | 0 | 0 | 1 | 0 | 0 | 0 | Not treated | 0 | 1090 (A) |
| 23 | 75.6/M | +19/20/5/23/K, −10 | LN | Diffuse | 0 | 26 | Interstitial | 0 | 0 | ND | 4 | 0 | 1 | 0 | 1 | 1 | ND | 19 | 0 | 729 (D) |
| 30 | 79.4/M | +20/5/23dim/K, −10 | LN | Nodular | 1 | 41 | Nodular | 1 | 0 | 3 | 4 | 1 | 1 | 0 | 1 | 1 | 0 | 16 | 0 | 159 (D) |
| 32 | 77.4/F | +20/5/23dim/L, −10 | Spleen | Diffuse | 0 | 26 | Nodular | 1 | 0 | 3 | 4 | 1 | 1 | 0 | 0 | 1 | 0 | 14 | 0 | 494 (D) |
| 48 | 76.0/M | ND | Prostate | Diffuse | 1 | 79 | ND | 1 | 0 | ND | 4 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 411 (D) |
| 92 | 69.8/F | +20/5/K, −23/10 | BM | NA | ND | 20 | Diffuse, nodular | 1 | 0 | 3 | 4 | 1 | 0 | 0 | 1 | 1 | 0 | 42 | 0 | 536 (D) |
| 101 | 63.9/M | +19/20/5/K, −23/10 | Spleen | Diffuse | 0 | 38 | Nodular | 1 | 0 | 1 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 453 (D) |
| 104 | 71.4/M | +20/5/23dim/L, −10 | BM | NA | 0 | 27 | Diffuse | 1 | 0 | ND | 4 | ND | 1 | 1 | 1 | 1 | 0 | 6 | 0 | 146 (D) |
| 123 | 68.1/M | +20/5/23dimL, −10 | BM | NA | 0 | 45 | Paratrabecular | 1 | 0 | ND | 4 | ND | 1 | 1 | ND | 0 | 0 | 15 | 0 | 514 (D) |
| 125 | 68.9/M | +19/20/23dim/K, −5/10 | BM | NA | 0 | 4 | Interstitial, nodular | 1 | 0 | ND | 4 | ND | ND | ND | 1 | 0 | 1 | 35 | 0 | 477 (D) |
| 139 | 64.1/M | +20/5/K, −23/10 | BM | NA | 0 | nd | Interstitial, small groups | 1 | 1 | 3 | 4 | 0 | 0 | 0 | 1 | 0 | 0 | Not treated | 0 | 1038 (A) |
| 167 | 48.4/M | +20/5/K, −23/10 | LN | Diffuse | 0 | 35 | Diffuse | 0 | 0 | 1 | 4 | 1 | 0 | 0 | 1 | 1 | 0 | 8 | 1 | 924 (D) |
| Patient . | Age, y/sex . | CD markers by flow cytometry . | Diagnostic tissue . | Growth pattern lymphoid tissue . | Blastoid variant . | MIB1, % . | Growth pattern BM . | p53* . | Indolent† . | MIPI . | Stage . | Splenomegaly . | > 4 nodal sites . | Extra nodal . | Leukemic . | B symptoms . | ECOG score > 2 . | TTT, d . | ASCT . | Follow-up, d (status) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 89.9/M | +/5/L, −23/10 | LN | Diffuse | 0 | 13 | Nodular | 0 | 0 | 3 | 4 | 0 | 1 | 0 | 0 | 0 | 0 | 24 | 0 | 1775 (D) |
| 15 | 87.1/F | +20/5/23dim/L, −10 | Stomach | NA | 0 | 12 | Nodular | 0 | 1 | 3 | 4 | 0 | 0 | 1 | 0 | 0 | 0 | Not treated | 0 | 1090 (A) |
| 23 | 75.6/M | +19/20/5/23/K, −10 | LN | Diffuse | 0 | 26 | Interstitial | 0 | 0 | ND | 4 | 0 | 1 | 0 | 1 | 1 | ND | 19 | 0 | 729 (D) |
| 30 | 79.4/M | +20/5/23dim/K, −10 | LN | Nodular | 1 | 41 | Nodular | 1 | 0 | 3 | 4 | 1 | 1 | 0 | 1 | 1 | 0 | 16 | 0 | 159 (D) |
| 32 | 77.4/F | +20/5/23dim/L, −10 | Spleen | Diffuse | 0 | 26 | Nodular | 1 | 0 | 3 | 4 | 1 | 1 | 0 | 0 | 1 | 0 | 14 | 0 | 494 (D) |
| 48 | 76.0/M | ND | Prostate | Diffuse | 1 | 79 | ND | 1 | 0 | ND | 4 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 411 (D) |
| 92 | 69.8/F | +20/5/K, −23/10 | BM | NA | ND | 20 | Diffuse, nodular | 1 | 0 | 3 | 4 | 1 | 0 | 0 | 1 | 1 | 0 | 42 | 0 | 536 (D) |
| 101 | 63.9/M | +19/20/5/K, −23/10 | Spleen | Diffuse | 0 | 38 | Nodular | 1 | 0 | 1 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 453 (D) |
| 104 | 71.4/M | +20/5/23dim/L, −10 | BM | NA | 0 | 27 | Diffuse | 1 | 0 | ND | 4 | ND | 1 | 1 | 1 | 1 | 0 | 6 | 0 | 146 (D) |
| 123 | 68.1/M | +20/5/23dimL, −10 | BM | NA | 0 | 45 | Paratrabecular | 1 | 0 | ND | 4 | ND | 1 | 1 | ND | 0 | 0 | 15 | 0 | 514 (D) |
| 125 | 68.9/M | +19/20/23dim/K, −5/10 | BM | NA | 0 | 4 | Interstitial, nodular | 1 | 0 | ND | 4 | ND | ND | ND | 1 | 0 | 1 | 35 | 0 | 477 (D) |
| 139 | 64.1/M | +20/5/K, −23/10 | BM | NA | 0 | nd | Interstitial, small groups | 1 | 1 | 3 | 4 | 0 | 0 | 0 | 1 | 0 | 0 | Not treated | 0 | 1038 (A) |
| 167 | 48.4/M | +20/5/K, −23/10 | LN | Diffuse | 0 | 35 | Diffuse | 0 | 0 | 1 | 4 | 1 | 0 | 0 | 1 | 1 | 0 | 8 | 1 | 924 (D) |
MCL indicates mantle cell lymphoma; CD, cluster of differentiation; MIB1, proliferation measured by Ki-67 staining; BM, bone marrow; MIPI, MCL International Prognostic Index; ECOG, Eastern Cooperative Oncology Group; TTT, time to treatment; ASCT, autologous stem cell transplantation; LN, lymph node; 0, negative; 1, positive; D, dead; NA, not applicable; A, alive; and ND, not done.
p53 positivity in > 20% of the tumor cells by immunohistochemistry.
Indolent disease, not requiring treatment within the first 2 years after diagnosis.